دورية أكاديمية
أعرض في EDS

Liraglutide treatment attenuates inflammation markers in the cardiac, cerebral and renal microvasculature in streptozotocin-induced diabetic rats.

التفاصيل البيبلوغرافية
العنوان: Liraglutide treatment attenuates inflammation markers in the cardiac, cerebral and renal microvasculature in streptozotocin-induced diabetic rats.
المؤلفون: Baylan U; Department of Pathology, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.; Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands., Korn A; Department of Pathology, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.; Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands., Emmens RW; Department of Pathology, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.; Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands., Schalkwijk CG; Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands.; Cardiovascular Research Institute Maastricht (CARIM), Maastricht, the Netherlands., Niessen HWM; Department of Pathology, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.; Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands., Krijnen PAJ; Department of Pathology, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.; Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands., Simsek S; Department of Internal Medicine, Alkmaar, the Netherlands.; Department of Internal Medicine, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.
المصدر: European journal of clinical investigation [Eur J Clin Invest] 2022 Sep; Vol. 52 (9), pp. e13807. Date of Electronic Publication: 2022 May 07.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wiley Country of Publication: England NLM ID: 0245331 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2362 (Electronic) Linking ISSN: 00142972 NLM ISO Abbreviation: Eur J Clin Invest Subsets: MEDLINE
أسماء مطبوعة: Publication: Oxford : Wiley
Original Publication: Berlin, New York, Springer-Verlag, on behalf of the European Society for Clinical Investigation.
مواضيع طبية MeSH: Diabetes Mellitus, Experimental*/drug therapy , Diabetes Mellitus, Experimental*/metabolism , Liraglutide*/pharmacology , Liraglutide*/therapeutic use, Animals ; Blood Glucose ; Endothelial Cells/metabolism ; Hypoglycemic Agents/pharmacology ; Hypoglycemic Agents/therapeutic use ; Inflammation/drug therapy ; Intercellular Adhesion Molecule-1 ; Kidney/metabolism ; Microvessels ; Rats ; Rats, Sprague-Dawley ; Streptozocin/toxicity ; Vascular Cell Adhesion Molecule-1
مستخلص: Background: Diabetes mellitus (DM) induces cardiac and cerebral microvascular dysfunction via increased glycation, oxidative stress and endothelial activation. Liraglutide, a glucagon-like peptide-1 analogue, inhibited NOX2 and adhesion molecules in isolated endothelial cells. Here, we have studied how Liraglutide affects advanced glycation, NOX expression and inflammation of the cardiac, cerebral and renal microvasculature in diabetic rats.
Methods: DM was induced in Sprague-Dawley rats (n = 15) via intraperitoneal streptozotocin (STZ) injection (60 mg/kg bodyweight). Ten control rats remained nondiabetic. From day 9 post-STZ injection, Liraglutide (200 μg/kg bodyweight; n = 7) or vehicle (n = 8) was injected subcutaneously daily until termination on day 29. The advanced glycation endproduct N-ε-(carboxymethyl)lysine (CML), NOX2, NOX4, ICAM-1 and VCAM-1 were subsequently immunohistochemically analysed and quantified to compare Liraglutide treatment with placebo.
Results: In the heart, Liraglutide treatment significantly reduced the DM-increased scores/cm 2 for CML in both ventricles (from 253 ± 53 to 72 ± 12; p = .003) and atria (343 ± 29 to 122 ± 8; p = .0001) and for NOX2, ICAM-1 and VCAM-1, but not for NOX4. Also in the cerebrum and cerebellum of the brain, Liraglutide significantly reduced the scores/cm 2 for CML (to 60 ± 7 (p = .0005) and 47 ± 13 (p = .02), respectively), and for NOX2 and NOX4. In the kidney, the DM-induced expression of ICAM-1 and VCAM-1 was decreased in the blood vessels and glomeruli by Liraglutide treatment. Liraglutide did not affect blood glucose levels or bodyweight.
Conclusions: Our study implies that Liraglutide protects the cardiac, cerebral and renal microvasculature against diabetes-induced dysfunction, independent of lowering blood glucose in a type 1 diabetes rat model.
(© 2022 The Authors. European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.)
References: Cell Physiol Biochem. 2018;45(4):1717-1730. (PMID: 29490301)
Biochim Biophys Acta. 2004 Mar 22;1636(2-3):82-9. (PMID: 15164755)
Biochim Biophys Acta. 2013 Dec;1832(12):2216-31. (PMID: 23994612)
J Am Heart Assoc. 2016 Nov 14;5(11):. (PMID: 27930353)
Diab Vasc Dis Res. 2011 Apr;8(2):117-24. (PMID: 21562063)
Lancet. 2018 Aug 11;392(10146):477-486. (PMID: 30129464)
Diabetes Care. 2015 Dec;38(12):2250-7. (PMID: 26486191)
Atherosclerosis. 2015 May;240(1):250-9. (PMID: 25818251)
Circulation. 2011 Sep 6;124(10):1151-9. (PMID: 21844073)
Exp Biol Med (Maywood). 2018 Jan;243(1):34-44. (PMID: 29171288)
Endocrinology. 2018 Apr 1;159(4):1570-1584. (PMID: 29444223)
Peptides. 2019 Jan;111:26-32. (PMID: 30227157)
Eur J Clin Invest. 2022 Sep;52(9):e13807. (PMID: 35488737)
J Am Heart Assoc. 2018 Sep 18;7(18):e009379. (PMID: 30371206)
Diabetes. 2000 Mar;49(3):466-75. (PMID: 10868970)
Am J Health Syst Pharm. 2019 Oct 15;76(21):1739-1748. (PMID: 31612934)
Diabetes. 2015 Jul;64(7):2624-35. (PMID: 25720388)
Biosci Rep. 2018 Feb 12;:. (PMID: 29440457)
Diabetologia. 2011 Apr;54(4):965-78. (PMID: 21253697)
Regul Pept. 2012 Feb 10;174(1-3):46-52. (PMID: 22120833)
BMC Neurol. 2007 Oct 16;7:35. (PMID: 17939855)
Eur J Clin Invest. 2010 Jan;40(1):35-53. (PMID: 20055895)
Diabetologia. 2006 Jun;49(6):1447-8. (PMID: 16598451)
Int J Mol Sci. 2019 Aug 02;20(15):. (PMID: 31382355)
Diabetes Obes Metab. 2020 Oct;22(10):1742-1752. (PMID: 32424935)
Diabetes. 2013 May;62(5):1697-708. (PMID: 23364453)
Diabetes. 2003 Aug;52(8):2137-43. (PMID: 12882933)
Genet Mol Res. 2013 Dec 13;12(4):6692-707. (PMID: 24391011)
N Engl J Med. 2017 Aug 31;377(9):839-848. (PMID: 28854085)
Eur J Endocrinol. 2008 May;158(5):655-60. (PMID: 18426823)
Antioxid Redox Signal. 2009 Dec;11(12):3071-109. (PMID: 19489690)
J Int Med Res. 2017 Dec;45(6):1901-1929. (PMID: 28643578)
N Engl J Med. 2016 Jul 28;375(4):311-22. (PMID: 27295427)
Mol Med Rep. 2017 Sep;16(3):3421-3426. (PMID: 28713911)
FEBS Lett. 1995 Jan 30;358(3):219-24. (PMID: 7843404)
Curr Opin Lipidol. 2012 Dec;23(6):540-7. (PMID: 23160401)
J Transl Med. 2013 Mar 28;11:84. (PMID: 23537041)
Diabetologia. 2010 Oct;53(10):2256-63. (PMID: 20593161)
Diabetologia. 2020 Aug;63(8):1626-1636. (PMID: 32451572)
Int J Cardiol. 2016 Apr 15;209:74-6. (PMID: 26882189)
Diabetes Res Clin Pract. 2021 Apr;174:108724. (PMID: 33647332)
Lancet Diabetes Endocrinol. 2020 Apr;8(4):325-336. (PMID: 32135131)
Am J Physiol Endocrinol Metab. 2001 May;280(5):E685-94. (PMID: 11287350)
Diabetes Care. 2016 Jun;39(6):1027-35. (PMID: 27208343)
معلومات مُعتمدة: Novo Nordisk
فهرسة مساهمة: Keywords: CML; GLP-1 analogue; ICAM-1 (CD54); Liraglutide; NADPH oxidases; VCAM-1 (CD106); advanced glycation endproducts; cerebral vasculature; diabetes mellitus; intramyocardial vasculature; renal vasculature
المشرفين على المادة: 0 (Blood Glucose)
0 (Hypoglycemic Agents)
0 (Vascular Cell Adhesion Molecule-1)
126547-89-5 (Intercellular Adhesion Molecule-1)
5W494URQ81 (Streptozocin)
839I73S42A (Liraglutide)
تواريخ الأحداث: Date Created: 20220430 Date Completed: 20220819 Latest Revision: 20221015
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC9539594
DOI: 10.1111/eci.13807
PMID: 35488737
قاعدة البيانات: MEDLINE
الوصف
تدمد:1365-2362
DOI:10.1111/eci.13807